BNF for Children July 2022 Update

This update contains 3 significant changes, 2 new monographs, and 1 new preparation.

Significant Changes:

• Anagrelide: risk of thrombosis, including cerebral infarction, if treatment discontinued abruptly [MHRA/CHM advice].
• Denosumab (Prolia®): should not be used in patients under 18 years due to the risk of serious hypercalcaemia [MHRA/CHM advice].
• Tacrolimus: updated pregnancy, breast-feeding and monitoring advice.

New Monographs:

• Aubagio® [teriflunomide].
• Ngenla® [somatrogon].

New Preparations:

• Ogluo® [glucagon].